Physician profile
Hossein Samadi
NPI 1124224324
$3,133.22
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,372 · 2020: $736 · 2022: $25.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $642.82 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $506.52 | 2019-2020 | |
| Alkermes, INC. | $488.25 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $387.64 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $316.82 | 2019-2020 | |
| Allergan, INC. | $289.00 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $182.26 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $158.42 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $84.70 | 2019-2020 | |
| Indivior INC. | $45.01 | 2020 | |
| Lundbeck LLC | $19.95 | 2019 | |
| Acadia Pharmaceuticals INC | $11.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hossein Samadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.